The clinical applications of hydrophobic interaction chromatography span diverse biopharmaceutical modalities, from monoclonal antibodies and antibody-drug conjugates to biosimilars and recombinant proteins. The Hydrophobic Interaction Chromatography Market is benefiting from this diverse demand, valued at USD 508.5 million in 2025 and projected to reach USD 1,048.0 million by 2035 at a CAGR of 7.5%. This article explores the clinical applications driving market growth.

Monoclonal Antibody Applications

Aggregate and HCP Removal

Monoclonal antibodies constitute the backbone of the market because nearly every commercial mAb process includes at least one HIC polishing step for aggregate and host-cell protein removal. HIC is the preferred orthogonal mode after Protein A capture. mAb purification is the largest application segment.

Process Development and Scale-Up

Each mAb candidate moving into Phase III typically requires two to three chromatographic polishing steps. Commercial-scale manufacturing locks in validated column and resin specifications for the product's entire lifecycle. HIC is essential for mAb process development.

Continuous Manufacturing Integration

FDA guidance formally recognized continuous chromatography as a viable downstream platform. Multi-column continuous HIC is gaining adoption in commercial mAb manufacturing. Continuous processing is reshaping mAb purification.

Antibody-Drug Conjugate Applications

DAR Species Resolution

ADCs present unique purification challenges because drug-to-antibody ratio variants must be resolved to tight specifications. HIC is one of very few techniques capable of separating DAR species at preparative scale. ADC purification is a key driver of HIC demand.

Conjugate Purification

HIC is essential for removing unconjugated payload and achieving target DAR distribution. ADC purification requires high-resolution hydrophobicity-based separations. Conjugate purification is a specialized HIC application.

Process Intensification

Manufacturers are investing in dedicated HIC skids and high-resolution resins optimized for conjugate separations. Process intensification is driving HIC adoption in ADC manufacturing. ADC pipelines are expanding HIC requirements.

Biosimilar Applications

Platform Process Standardization

Each approved biosimilar establishes a fixed purification process that consumes resins and columns throughout its commercial life. Biosimilar manufacturers rely on HIC polishing as a standard platform step. Biosimilars create recurring HIC demand.

Cost-Effective Purification

Biosimilar manufacturers require cost-effective purification processes to compete with reference products. HIC offers a balance of resolution and cost for biosimilar manufacturing. Cost-effectiveness drives HIC adoption in biosimilars.

Regulatory Acceptance

FDA and EMA accept HIC polishing when supported by validated clearance data. Biosimilar applicants routinely include HIC in their downstream platform descriptions. Regulatory acceptance supports HIC adoption.

Recombinant Protein Applications

Enzyme Purification

Recombinant proteins and industrial enzymes require HIC for polishing and impurity removal. HIC is used for enzyme purification at commercial scale. Enzyme purification is a stable HIC application.

Fusion Protein Processing

Fusion protein manufacturing often incorporates HIC steps for aggregate removal. HIC is used for fusion protein polishing. Fusion proteins are a growing application area.

Vaccine Antigen Purification

Vaccine antigen purification may employ HIC for polishing. HIC is used for certain vaccine manufacturing processes. Vaccine production is a niche HIC application.

Cell and Gene Therapy Applications

Viral Vector Purification

Viral vector purification workflows increasingly incorporate hydrophobic interaction steps for removing process-related impurities. HIC is emerging as a polishing step for viral vectors. CGT purification is a new HIC application.

Lipid Nanoparticle Processing

Lipid nanoparticle purification may employ HIC for impurity removal. HIC is being evaluated for LNP manufacturing. Lipid nanoparticles are an emerging HIC application.

Process Development for ATMPs

Advanced therapy medicinal products require specialized purification approaches. HIC is being developed for ATMP manufacturing processes. ATMPs are expanding HIC applications.

End-User Applications

Pharma and Biopharma Companies

Pharma and biopharma companies account for the majority of HIC demand because they operate the largest installed base of validated chromatography systems. In-house manufacturing is the largest end-user segment.

CDMOs

CDMOs are the fastest-growing end-user segment, driven by a structural shift toward outsourced manufacturing. CDMOs require flexible, multi-product purification platforms. Outsourcing is driving CDMO HIC demand.

Academic and Research Institutes

Academic and research institutes use HIC for protein research and method development. Research applications are a stable demand source. Academic research is a niche HIC application.

Future Clinical Directions

Continuous Processing Integration

Multi-column continuous HIC is gaining regulatory acceptance. Continuous processing can cut buffer volumes by 40-60% relative to batch processes. Continuous manufacturing is reshaping HIC adoption.

Personalized Medicine Applications

Personalized medicine approaches may require HIC for specialized purification. Personalized therapies could expand HIC applications. Customization is a future direction.

Integrated Purification Platforms

Integrated platforms combining HIC with other chromatography modes are emerging. Integrated platforms improve process efficiency and product quality. Integration is a key future trend.

The Hydrophobic Interaction Chromatography Market continues expanding across clinical applications, from mAbs to ADCs. HIC is essential for modern biopharmaceutical manufacturing, supporting production of life-saving biologics across diverse product classes.